|13th August 2020||William L. Ostrander||4,440||Payment by withholding||$1.83||$8,125.20|
|13th August 2020||William L. Ostrander||15,625||Exercise of derivative||$0.52||$8,125.00|
|16th June 2020||John K A Prendergast||99,000||Grant/award etc.||$0.00|
|2nd January 2020||Jeffrey Alan Wolf||1,980,000||Grant/award etc.||$0.00|
|2nd January 2020||John K A Prendergast||400,000||Grant/award etc.||$0.00|
|31st December 2019||Jeffrey Alan Wolf||900,000||Grant/award etc.||$0.00|
|24th June 2019||John K A Prendergast||84,000||Grant/award etc.||$0.00|
|1st January 2019||John K A Prendergast||300,000||Grant/award etc.||$0.00|
|1st January 2019||Jeffrey Alan Wolf||800,000||Grant/award etc.||$0.00|
|1st January 2019||Jeff Tobin Hutchins||143,140||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Heat Biologics, Inc. is a clinical stage company. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot. Its product candidates are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.